Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1982 Mar;45(3):587–595.

The activation of the alternative pathway C3 convertase by human plasma kallikrein.

R G DiScipio
PMCID: PMC1555245  PMID: 6916710

Abstract

Human plasma kallikrein can replace factor D for the activation of the alternative pathway C3 convertase of human complement. The factor B cleavage patterns by factor D and kallikrein are indistinguishable. The ability of kallikrein to cleave factor B is influenced by the magnesium ion concentration and the C3b concentration. Factor D is about ten-fold more effective on a molar basis, for the alternative pathway C3 convertase activation than is kallikrein. The physiological role of the action of kallikrein on the alternative pathway C3 convertase is discussed.

Full text

PDF
587

Images in this article

590Figure 1
on p.590

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ACKERS G. K. MOLECULAR EXCLUSION AND RESTRICTED DIFFUSION PROCESSES IN MOLECULAR-SIEVE CHROMATOGRAPHY. Biochemistry. 1964 May;3:723–730. doi: 10.1021/bi00893a021. [DOI] [PubMed] [Google Scholar]
  2. Bouma B. N., Miles L. A., Beretta G., Griffin J. H. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry. 1980 Mar 18;19(6):1151–1160. doi: 10.1021/bi00547a018. [DOI] [PubMed] [Google Scholar]
  3. Brade V., Nicholson A., Bitter-Suermann D., Hadding U. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes. J Immunol. 1974 Dec;113(6):1735–1743. [PubMed] [Google Scholar]
  4. Brade V., Nicholson A., Lee G. D., Mayer M. M. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics. J Immunol. 1974 May;112(5):1845–1854. [PubMed] [Google Scholar]
  5. Christie D. L., Gagnon J., Porter R. R. Partial sequence of human complement component factor B: novel type of serine protease. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4923–4927. doi: 10.1073/pnas.77.8.4923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cuatrecasas P. Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads. J Biol Chem. 1970 Jun;245(12):3059–3065. [PubMed] [Google Scholar]
  7. Curman B., Sandberg-Trägårdh L., Peterson P. A. Chemical characterization of human factor B of the alternate pathway of complement activation. Biochemistry. 1977 Nov 29;16(24):5368–5375. doi: 10.1021/bi00643a031. [DOI] [PubMed] [Google Scholar]
  8. Davis A. E., 3rd Active site amino acid sequence of human factor D. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4938–4942. doi: 10.1073/pnas.77.8.4938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. DiScipio R. G. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan. Biochem J. 1981 Dec 1;199(3):485–496. doi: 10.1042/bj1990485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dieminger L., Vogt W., Lynen R. Purification and some properties of factor D of the human properdin system. Z Immunitatsforsch Immunobiol. 1976 Nov;152(3):231–243. [PubMed] [Google Scholar]
  11. Dierich M. P., Hadding U., König W., Limbert M., Schorlemmer H. U., Bitter-Suermann D. Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry. 1974 Sep;11(9):527–532. doi: 10.1016/0019-2791(74)90242-0. [DOI] [PubMed] [Google Scholar]
  12. Fujikawa K., Heimark R. L., Kurachi K., Davie E. W. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry. 1980 Apr 1;19(7):1322–1330. doi: 10.1021/bi00548a010. [DOI] [PubMed] [Google Scholar]
  13. Han Y. N., Kato H., Iwanaga S., Komiya M. Actions of urinary kallikrein, plasmin, and other kininogenases on bovine plasma high-molecular-weight kininogen. J Biochem. 1978 Jan;83(1):223–235. doi: 10.1093/oxfordjournals.jbchem.a131895. [DOI] [PubMed] [Google Scholar]
  14. Heimark R. L., Davie E. W. Isolation and characterization of bovine plasma prekallikrein (Fletcher factor). Biochemistry. 1979 Dec 11;18(25):5743–5750. doi: 10.1021/bi00592a035. [DOI] [PubMed] [Google Scholar]
  15. Johnson D. M., Gagnon J., Reid K. B. Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site. Biochem J. 1980 Jun 1;187(3):863–874. doi: 10.1042/bj1870863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kaplan A. P. Initiation of the intrinsic coagulation and fibrinolytic pathways of man: the role of surfaces, hageman factor, prekallikrein, high molecular weight kininogen, and factor XI. Prog Hemost Thromb. 1978;4:127–175. [PubMed] [Google Scholar]
  17. Kazatchkine M. D., Fearon D. T., Austen K. F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol. 1979 Jan;122(1):75–81. [PubMed] [Google Scholar]
  18. Kisiel W., Ericsson L. H., Davie E. W. Proteolytic activation of protein C from bovine plasma. Biochemistry. 1976 Nov 2;15(22):4893–4900. doi: 10.1021/bi00667a022. [DOI] [PubMed] [Google Scholar]
  19. Kurachi K., Schmer G., Hermodson M. A., Teller D. C., Davie E. W. Characterization of human, bovine, and horse antithrombin III. Biochemistry. 1976 Jan 27;15(2):368–373. doi: 10.1021/bi00647a020. [DOI] [PubMed] [Google Scholar]
  20. Lesavre P. H., Hugli T. E., Esser A. F., Müller-Eberhard H. J. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol. 1979 Aug;123(2):529–534. [PubMed] [Google Scholar]
  21. Lesavre P. H., Müller-Eberhard H. J. Mechanism of action of factor D of the alternative complement pathway. J Exp Med. 1978 Dec 1;148(6):1498–1509. doi: 10.1084/jem.148.6.1498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mandle R., Jr, Kaplan A. P. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis. J Biol Chem. 1977 Sep 10;252(17):6097–6104. [PubMed] [Google Scholar]
  23. Mole J. E., Niemann M. A. Structural evidence that complement factor B constitutes a novel class of serine protease. J Biol Chem. 1980 Sep 25;255(18):8472–8476. [PubMed] [Google Scholar]
  24. Müller-Eberhard H. J., Götze O. C3 proactivator convertase and its mode of action. J Exp Med. 1972 Apr 1;135(4):1003–1008. doi: 10.1084/jem.135.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Müller-Eberhard H. J., Schreiber R. D. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol. 1980;29:1–53. doi: 10.1016/s0065-2776(08)60042-5. [DOI] [PubMed] [Google Scholar]
  26. Nagase H., Barrett A. J. Human plasma kallikrein. A rapid purification method with high yield. Biochem J. 1981 Jan 1;193(1):187–192. doi: 10.1042/bj1930187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Parkes C., DiScipio R. G., Kerr M. A., Prohaska R. The separation of functionally distinct forms of the third component of human complement (C3). Biochem J. 1981 Mar 1;193(3):963–970. doi: 10.1042/bj1930963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Reid K. B., Porter R. R. The proteolytic activation systems of complement. Annu Rev Biochem. 1981;50:433–464. doi: 10.1146/annurev.bi.50.070181.002245. [DOI] [PubMed] [Google Scholar]
  29. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]
  30. Thaler E., Schmer G. A simple two-step isolation procedure for human and bovine antithrombin II/III (heparin cofactor): a comparison of two methods. Br J Haematol. 1975 Oct;31(2):233–243. doi: 10.1111/j.1365-2141.1975.tb00853.x. [DOI] [PubMed] [Google Scholar]
  31. Venneröd A. M., Laake K., Solberg A. K., Strömland S. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thromb Res. 1976 Nov;9(5):457–466. doi: 10.1016/0049-3848(76)90201-2. [DOI] [PubMed] [Google Scholar]
  32. Vogt W., Dames W., Schmidt G., Dieminger L. Complement activation by the properdin system: formation of a stoichiometric. C3 cleaving complex of properdin factor B with C36. Immunochemistry. 1977 Mar;14(3):201–205. doi: 10.1016/0019-2791(77)90195-1. [DOI] [PubMed] [Google Scholar]
  33. Volanakis J. E., Bhown A., Bennett J. C., Mole J. E. Partial amino acid sequence of human factor D:homology with serine proteases. Proc Natl Acad Sci U S A. 1980 Feb;77(2):1116–1119. doi: 10.1073/pnas.77.2.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Volanakis J. E., Schrohenloher R. E., Stroud R. M. Human factor D of the alternative complement pathway: purification and characterization. J Immunol. 1977 Jul;119(1):337–342. [PubMed] [Google Scholar]
  35. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  36. Wuepper K. D. Prekallikrein deficiency in man. J Exp Med. 1973 Dec 1;138(6):1345–1355. doi: 10.1084/jem.138.6.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES